Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 17/20 | 0.59 |
| ▸ | PRKAG1 | P54619 | 17/20 | 0.59 |
| ▸ | PRKAA2 | P54646 | 17/20 | 0.59 |
| ▸ | PRKAA1 | Q13131 | 17/20 | 0.59 |
| ▸ | PRKAG3 | Q9UGI9 | 17/20 | 0.59 |
| ▸ | PRKAG2 | Q9UGJ0 | 17/20 | 0.59 |
| ▸ | PRKAB1 | Q9Y478 | 17/20 | 0.59 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | F3 | P13726 | 1/20 | 0.56 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23622947 | 0.93 | F7 (0.56) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL10478126 | 0.91 | KDM4E (0.60) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL17429453 | 0.85 | PRKAB2 (0.59) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL23612266 | 0.85 | PRKAG1 (0.66) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL30416918 | 0.85 | PRKAB2 (0.59) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL17417592 | 0.81 | CYP2C19 (0.52) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL6327581 | 0.81 | PRKAG1 (0.49) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL22790098 | 0.79 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL17417739 | 0.79 | PRKAB2 (0.51) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL15300738 | 0.79 | PRKAB2 (0.59) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN LLC (US) | 2017-06-15 | — | — | US | disclosed |
| EP-3166940-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | Alpharmagen, LLC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434724-B2 | Quinuclidines for modulating alpha 7 activity | ALPHARMAGEN, LLC (US) | 2016-09-06 | — | — | US | disclosed |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | ALPHARMAGEN, LLC | 2016-01-14 | — | — | US | disclosed |
| WO-2016007630-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN, LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016007630-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7 -NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | ALPHARMAGEN, LLC (US) | 2016-01-14 | — | — | WO | disclosed |
| EP-1904477-B1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2009-01-21 | — | — | EP | disclosed |
| EP-1912976-B1 | INDOL-3-YL-CARBONYL-PIPERIDIN-BENZOIMIDAZOLE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2008-11-12 | — | — | EP | disclosed |
| CN-101268067-A | Indol-3-yl-carbonyl-piperidine-benzimidazole derivatives as V1A receptor antagonists | HOFFMANN LA ROCHE (CH) | 2008-09-17 | — | — | CN | disclosed |
| CN-101253164-A | Indol-3-carbonyl-spiro-piperidine derivatives as v1a receptor antagonists | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | CN | disclosed |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | BISSANTZ CATERINA | 2008-06-19 | — | — | US | disclosed |
| EP-1904477-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7332501-B2 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as V1a receptor antagonists | HOFFMANN-LA ROCHE INC. (US) | 2008-02-19 | — | — | US | disclosed |
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | US | disclosed |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | disclosed |
| WO-2007006688-A1 | INDOL-3-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027173-A1 | Indol-3-yl-carbonyl-spiro-piperidine derivatives as Vla receptor antagonists | AVPR1A, AVPR2, AVPR1B | PRKAB2 4448/4885PRKAG1 3882/4885PRKAA2 4075/4885 |
| US-20070021463-A1 | Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives | AVPR1A, AVPR2, AVPR1B | PRKAB2 3739/4885PRKAG1 2880/4885PRKAA2 3675/4885 |
| US-20080146557-A1 | INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS VIa RECEPTOR ANTAGONISTS | AVPR1A, AVPR2, OXTR | PRKAB2 4396/4885PRKAG1 3824/4885PRKAA2 3812/4885 |
| US-20160009706-A1 | QUINUCLIDINES FOR MODULATING ALPHA 7 ACTIVITY | CHRNA7, CHRNA2, CHRNA5 | PRKAB2 666/4885PRKAG1 502/4885PRKAA2 1015/4885 |
| US-20170166561-A1 | QUINUCLIDINE COMPOUNDS FOR MODULATING ALPHA7-NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVITY | CHRNA7, CHRNA2, CHRNA6 | PRKAB2 961/4885PRKAG1 729/4885PRKAA2 1508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.